CRISPR targeting of FOXL2 c. 402C >G mutation reduces malignant phenotype in granulosa tumor cells and identifies anti‐tumoral compounds
Molecular Oncology · 2025
DOI: 10.1002/1878-0261.13799 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2025. Verfasst von Sandra Amarilla-Quintana und 17 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Investigación de Enfermedades Raras, Instituto de Salud Carlos III, Madrid, Spain. Hauptthemen laut MEDLINE: Forkhead Box Protein L2, Granulosa Cell Tumor, Mutation, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Grupo Español de Tumores Huerfanos e Infrecuentes, Fundación Científica Asociación Española Contra el Cáncer.
Abstract (Originalsprache)
Forkhead box L2 ( FOXL2 ) encodes a transcription factor essential for sex determination, and ovary development and maintenance. Mutations in this gene are implicated in syndromes involving premature ovarian failure and granulosa cell tumors (GCTs). This rare cancer accounts for less than 5% of diagnosed ovarian cancers and is causally associated with the FOXL2 c.402C>G, p.C134W mutation in 97% of the adult cases (AGCTs). In this study, we employed CRISPR technology to specifically eliminate the FOXL2 c.402C>G mutation in granulosa tumor cells. Our results show that this Cas9‐mediated strategy selectively targets the mutation without affecting the wild‐type allele. Granulosa cells lacking FOXL2 c.402C>G exhibit a reduced malignant phenotype, with significant changes in cell proliferation and invasion. Furthermore, these modified cells are more susceptible to dasatinib and ketoconazole. Transcriptomic and proteomic analyses reveal that CRISPR‐modified granulosa tumor cells shift their expression profiles towards a wild‐type‐like phenotype. Additionally, this altered expression signature has led to the identification of new compounds with antiproliferative and pro‐apoptotic effects on granulosa tumor cells. Our findings demonstrate the potential of CRISPR technology for the specific targeting and elimination of a mutation causing GCTs, highlighting its therapeutic promise for treating this rare ovarian cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Instituto de Investigación de Enfermedades Raras, Instituto de Salud Carlos III, Madrid, Spain.
- Programa de Doctorado en Ciencias Biomédicas y Salud Pública IMIENS-UNED-ISCIII, Escuela Internacional de Doctorado de la Universidad Nacional de Educación a Distancia (EIDUNED), Madrid, Spain.
- HM Hospitales-Centro Integral Oncológico HM Clara Campal, Madrid, Spain.
- Chronic Disease Program (UFIEC), Instituto de Salud Carlos III, Madrid, Spain.
- Department of Zoology, Genetics and Physical Anthropology, Universidade de Santiago de Compostela, Lugo, Spain.
- Confocal Microscopy Unit, Instituto de Salud Carlos III, Madrid, Spain.
ORCID-Profile: Borja Vilaplana-Martí, Rodrigo Barderas, Alberto Martín, Ignacio Pérez de Castro
Förderung
- Grupo Español de Tumores Huerfanos e Infrecuentes
- Fundación Científica Asociación Española Contra el Cáncer
Zitieren
APA
Amarilla-Quintana, S., Navarro, P., Hernández, I., Ramos, A., Montero-Calle, A., Cabezas-Sainz, P., Barrero, M. J., Megías, D., Vilaplana-Martí, B., Epifano, C., Gómez-Dominguez, D., Monzón, S., Cuesta, I., Sánchez, L., Barderas, R., García-Donas, J., Martín, A., & Pérez de Castro, I. (2025). CRISPR targeting of FOXL2 c. 402C >G mutation reduces malignant phenotype in granulosa tumor cells and identifies anti‐tumoral compounds. Molecular Oncology. https://doi.org/10.1002/1878-0261.13799
Vancouver
Amarilla-Quintana S, Navarro P, Hernández I, Ramos A, Montero-Calle A, Cabezas-Sainz P, et al. CRISPR targeting of FOXL2 c. 402C >G mutation reduces malignant phenotype in granulosa tumor cells and identifies anti‐tumoral compounds. Molecular Oncology. 2025. doi:10.1002/1878-0261.13799
BibTeX
@article{AmarillaQuintana2025,
author = {Amarilla-Quintana, Sandra and Navarro, Paloma and Hernández, Iván and Ramos, Alejandra and Montero-Calle, Ana and Cabezas-Sainz, Pablo and Barrero, Maria J and Megías, Diego and Vilaplana-Martí, Borja and Epifano, Carolina and Gómez-Dominguez, Déborah and Monzón, Sara and Cuesta, Isabel and Sánchez, Laura and Barderas, Rodrigo and García-Donas, Jesús and Martín, Alberto and Pérez de Castro, Ignacio},
title = {CRISPR targeting of FOXL2 c. 402C >G mutation reduces malignant phenotype in granulosa tumor cells and identifies anti‐tumoral compounds},
journal = {Molecular Oncology},
year = {2025},
doi = {10.1002/1878-0261.13799}
}
EUVIMED